Azacitidine effectively reduces TP53-mutant leukemic cell burden in secondary acute myeloid leukemia after cord blood transplantation

Tomomi TakeiDivision of Molecular Therapy, Advanced Clinical Research Center, the Institute of Medical Science, University of Tokyo, Tokyo, Japan;

Kazuaki YokoyamaDepartment of Hematology/Oncology, Research Hospital, the Institute of Medical Science, University of Tokyo, Tokyo, Japan;

Eigo ShimizuLaboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan;

Takaaki KonumaDepartment of Hematology/Oncology, Research Hospital, the Institute of Medical Science, University of Tokyo, Tokyo, Japan;

Satoshi TakahashiDepartment of Hematology/Oncology, Research Hospital, the Institute of Medical Science, University of Tokyo, Tokyo, Japan;

Rui YamaguchiLaboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan;

Seiya ImotoDivision of Health Medical Data Science, Health Intelligence Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan

Satoru MiyanoLaboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan;

Arinobu TojoDivision of Molecular Therapy, Advanced Clinical Research Center, the Institute of Medical Science, University of Tokyo, Tokyo, Japan; Correspondence[email protected]

http://orcid.org/0000-0001-9016-1948

show all

"Azacitidine effectively reduces TP53-mutant leukemic cell burden in secondary acute myeloid leukemia after cord blood transplantation." Leukemia & Lymphoma, 59(11), pp. 2755–2756

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Azacitidine effectively reduces TP53-mutant leukemic cell burden in secondary acute myeloid leukemia after cord blood transplantation

Information for

Open access

Opportunities

Help and information

Azacitidine effectively reduces TP53-mutant leukemic cell burden in secondary acute myeloid leukemia after cord blood transplantation

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature